)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Phio Pharmaceuticals
Phio Pharmaceuticals (PHIO) investor relations material
Phio Pharmaceuticals Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary5 Nov, 2026
Executive summary
PH-762 advanced toward a planned Phase 2b neoadjuvant study in cSCC, expected to begin in Q1 2027, subject to FDA feedback.
Phase 1b enrolled 22 patients and was completed in June 2026; Q3 operating expenses rose to $4.268 million and net loss was $4.160 million.
Financial highlights
Q3 operating expenses were $4.268 million versus $2.505 million YoY; net loss was $4.160 million versus $2.392 million, with no revenue generated.
Nine-month operating expenses were $12.703 million versus $6.686 million YoY; net loss was $12.301 million versus $6.327 million.
Cash and cash equivalents were $10.609 million at September 30, 2026, versus $21.031 million at December 31, 2025.
Outlook and guidance
FDA feedback on PH-762’s proposed development strategy was expected by the end of November 2026; Phase 2b initiation in cSCC was expected in Q1 2027.
PH-762 clinical supply manufacturing was expected in Q4 2026; a preliminary report from the pivotal GLP toxicology study was expected before year-end 2026.
Existing cash may not fund operations for at least 12 months from the financial statements’ release; additional capital is required to support operations and development.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Phio Pharmaceuticals
- PH-762 advances toward Q1 2027 Phase IIb after encouraging Phase Ib results.PHIO
Small Cap Growth Hybrid Investor Conference - Shareholders to vote on director elections, auditor ratification, and incentive plan amendment.PHIOProxy filing
- Virtual meeting to elect directors, ratify auditor, and expand equity plan; Board recommends FOR all.PHIOProxy filing
- PH-762 advanced in Phase 1b as net loss rose and cash runway extended into 2027.PHIOQ2 2026
- PH-762 achieved high tumor clearance and safety in cSCC, advancing toward further clinical trials.PHIOCorporate presentation
- PH-762 achieved 85% response in phase Ib; INTASYL offers precise, safe, and versatile gene silencing.PHIOFireside chat
- A new siRNA therapy shows promise for safer, localized skin cancer treatment and future expansion.PHIOFireside chat
- PH-762 demonstrated high safety and efficacy, positioning INTASYL for major skin cancer markets.PHIOLife Sciences Virtual Investor Forum
- Net loss rose to $4.0M as PH-762 Phase 1b completed; cash runway extends into 2027.PHIOQ1 2026
Next Phio Pharmaceuticals earnings date
Q4 20265 Mar, 2027
Phio Pharmaceuticals
Next Phio Pharmaceuticals earnings date
Q4 20265 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)